Product innovation, strategic acquisitions, and cloud-based SaaS models increase customer retention, cross-selling, and margins, enhancing long-term profitability and earnings stability. The company completed the Chemaxon acquisition and launched new products, while repurchasing $41M in stock and repricing a term loan.
Cyborg Score Rationale
Q3 2025 revenue of $104.6M (up 10% YoY) with 2025 guidance of $415-420M revenue (8-9% growth) demonstrates consistent growth. Net income improved to $1.5M from a $1.4M loss in Q3 2024, with adjusted EBITDA of $35.2M (34% margin). However, CERT underperformed the US Healthcare Services industry and US Market over the past year.
Top Insights
Provides comprehensive biosimulation solutions including the Simcyp platform for physiologically based pharmacokinetic simulation, model-informed drug development, and pharmacokinetics/pharmacodynamics prediction.
Strategic acquisitions (Chemaxon completed) and $41M stock repurchase signal shareholder-friendly capital allocation while expanding product portfolio.
Regulatory shifts and outsourcing trends providing tailwinds for biosimulation adoption among pharma customers.
Stock trading at 55.2% below fair value estimate, presenting potential valuation opportunity for contrarian investors.
Named Competitors
Simulations Plus Biosimulation Software — Competing biosimulation and drug development software platform
Schrödinger Computational Chemistry — Drug discovery computational chemistry and modeling solutions